G. Blackledge

5.1k total citations
125 papers, 3.8k citations indexed

About

G. Blackledge is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Reproductive Medicine. According to data from OpenAlex, G. Blackledge has authored 125 papers receiving a total of 3.8k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Oncology, 44 papers in Pulmonary and Respiratory Medicine and 32 papers in Reproductive Medicine. Recurrent topics in G. Blackledge's work include Ovarian cancer diagnosis and treatment (31 papers), Lymphoma Diagnosis and Treatment (21 papers) and Prostate Cancer Treatment and Research (18 papers). G. Blackledge is often cited by papers focused on Ovarian cancer diagnosis and treatment (31 papers), Lymphoma Diagnosis and Treatment (21 papers) and Prostate Cancer Treatment and Research (18 papers). G. Blackledge collaborates with scholars based in United Kingdom, Netherlands and Italy. G. Blackledge's co-authors include D. Crowther, C. W. E. Redman, C G Beardwell, F. Lawton, David Luesley, E Whitehead, S. M. SHALET, C. A. Meanwell, Geert J.C.M. Kolvenbag and Ian Todd and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and JNCI Journal of the National Cancer Institute.

In The Last Decade

G. Blackledge

124 papers receiving 3.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. Blackledge United Kingdom 34 1.3k 1.2k 985 914 853 125 3.8k
Howard W. Bruckner United States 34 924 0.7× 2.3k 1.9× 767 0.8× 554 0.6× 1.1k 1.3× 163 4.0k
Cinzia Orlandini Italy 29 877 0.7× 2.2k 1.8× 451 0.5× 217 0.2× 748 0.9× 74 3.7k
Atsuhiko Sakamoto Japan 28 397 0.3× 1.0k 0.8× 929 0.9× 401 0.4× 648 0.8× 126 3.5k
W. Lichtenegger Germany 35 548 0.4× 1.8k 1.5× 1.6k 1.6× 296 0.3× 983 1.2× 243 4.6k
Sigurd Lax Austria 39 867 0.6× 2.1k 1.8× 1.2k 1.2× 732 0.8× 646 0.8× 145 5.9k
Janine Mansi United Kingdom 41 2.3k 1.7× 3.5k 2.9× 316 0.3× 1.3k 1.4× 998 1.2× 123 6.5k
Peter E. Schwartz United States 41 577 0.4× 1.0k 0.9× 2.6k 2.6× 354 0.4× 998 1.2× 166 5.6k
Marc B. Garnick United States 40 1.8k 1.3× 1.2k 1.0× 387 0.4× 231 0.3× 1.6k 1.9× 133 4.9k
B. Weber France 29 536 0.4× 1.6k 1.3× 1.9k 2.0× 504 0.6× 824 1.0× 97 3.8k
Katherine Y. Look United States 29 595 0.4× 1.5k 1.2× 3.0k 3.0× 591 0.6× 1.7k 2.0× 93 5.3k

Countries citing papers authored by G. Blackledge

Since Specialization
Citations

This map shows the geographic impact of G. Blackledge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Blackledge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Blackledge more than expected).

Fields of papers citing papers by G. Blackledge

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Blackledge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Blackledge. The network helps show where G. Blackledge may publish in the future.

Co-authorship network of co-authors of G. Blackledge

This figure shows the co-authorship network connecting the top 25 collaborators of G. Blackledge. A scholar is included among the top collaborators of G. Blackledge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Blackledge. G. Blackledge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Blackledge, G. & Steven D. Averbuch. (2004). Gefitinib (‘Iressa’, ZD1839) and new epidermal growth factor receptor inhibitors. British Journal of Cancer. 90(3). 566–572. 66 indexed citations
2.
Blackledge, G., et al.. (2000). Anti-EGF receptor therapy. Prostate Cancer and Prostatic Diseases. 3(4). 296–302. 15 indexed citations
3.
4.
Stuart, N, Jane Warwick, G. Blackledge, et al.. (1996). A randomised phase III cross-over study of tamoxifen versus megestrol acetate in advanced and recurrent breast cancer. European Journal of Cancer. 32(11). 1888–1892. 29 indexed citations
5.
Blackledge, G.. (1996). High-dose bicalutamide monotherapy for the treatment of prostate cancer. Urology. 47(1). 44–47. 21 indexed citations
6.
Kehoe, Sean, et al.. (1992). Single agent high-dose cisplatin (200 mg m-2) treatment in ovarian carcinoma. British Journal of Cancer. 66(4). 717–719. 3 indexed citations
7.
Vantongelen, K., William P. Steward, G. Blackledge, Jaap Verweij, & A. Van Oosterom. (1991). EORTC joint ventures in quality control: Treatment-related variables and data acquisition in chemotherapy trials. European Journal of Cancer and Clinical Oncology. 27(2). 201–207. 33 indexed citations
8.
Redman, C. W. E., et al.. (1991). Out‐Patient Peritoneal Lavage Cytology In the Detection of Residual Epithelial Ovarian Cancer. Cytopathology. 2(6). 291–298. 2 indexed citations
9.
Schütte, J., Henning T. Mouridsen, Wendy A. Stewart, et al.. (1990). Ifosfamide plus doxorubicin in previously untreated patients with advanced soft tissue sarcoma. European Journal of Cancer and Clinical Oncology. 26(5). 558–561. 74 indexed citations
10.
Buxton, E. J., Natasha Saunders, G. Blackledge, et al.. (1990). The potential for adjuvant therapy in early-stage cervical cancer. Cancer Chemotherapy and Pharmacology. 26(S1). S17–S21. 4 indexed citations
11.
Blackledge, G., A. van Oosterom, Henning T. Mouridsen, et al.. (1990). Doxorubicin in relapsed soft tissue sarcoma: Justification of phase II evaluation of new drugs in this disease. European Journal of Cancer and Clinical Oncology. 26(2). 139–141. 24 indexed citations
12.
Blackledge, G., E. J. Buxton, J. Mould, et al.. (1990). Phase II studies of ifosfamide alone and in combination in cancer of the cervix. Cancer Chemotherapy and Pharmacology. 26(S1). S12–S16. 10 indexed citations
13.
Kerr, Rachel, J A Slack, M. F. G. STEVENS, et al.. (1990). Relationship between the pharmacokinetics and toxicity of mitozolomide. Cancer Chemotherapy and Pharmacology. 25(5). 352–354. 4 indexed citations
14.
Blackledge, G., Stuart Kaye, R. Taylor, et al.. (1989). A phase II study of mitozolomide in metastatic transitional cell carcinoma of the bladder. European Journal of Cancer and Clinical Oncology. 25(2). 391–392. 11 indexed citations
15.
Lawton, Frank, Martin Griffin, John F. Slack, & G. Blackledge. (1989). Urinary Polyamine Excretion Patterns in Patients with Epithelial Ovarian Cancer. Gynecologic and Obstetric Investigation. 28(4). 212–214. 12 indexed citations
16.
Luesley, David, G. Blackledge, Krystyna A. Kelly, et al.. (1988). FAILURE OF SECOND-LOOK LAPAROTOMY TO INFLUENCE SURVIVAL IN EPITHELIAL OVARIAN CANCER. The Lancet. 332(8611). 599–603. 69 indexed citations
17.
Meanwell, C. A., J. Mould, G. Blackledge, et al.. (1986). Phase II study of ifosfamide in cervical cancer.. PubMed. 70(6). 727–30. 40 indexed citations
18.
Whitehead, E, S. M. SHALET, G. Blackledge, et al.. (1983). The effect of combination chemotherapy on ovarian function in women treated for hodgkin's disease. Cancer. 52(6). 988–993. 167 indexed citations
19.
20.
Best, J.J.K., G. Blackledge, Ian Todd, et al.. (1978). Computed tomography of abdomen in staging and clinical management of lymphoma.. BMJ. 2(6153). 1675–1677. 47 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Howard W. Bruckner Breakdown of academic impact, for papers by Cinzia Orlandini Breakdown of academic impact, for papers by Atsuhiko Sakamoto Breakdown of academic impact, for papers by W. Lichtenegger Breakdown of academic impact, for papers by Sigurd Lax Breakdown of academic impact, for papers by Janine Mansi Breakdown of academic impact, for papers by Peter E. Schwartz Breakdown of academic impact, for papers by Marc B. Garnick Breakdown of academic impact, for papers by B. Weber Breakdown of academic impact, for papers by Katherine Y. Look
Rankless by CCL
2026